Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide as Maintenance Therapy in IgG4-Related Disease
NCT07719543Phase 3Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in immunoglobulin G4-related disease (IgG4-RD) comparing Lenalidomide Arm with Placebo Arm (2 arms). Primary endpoint: Cumulative relapse rate of IgG4-related disease at 52 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
lenalidomide
03
Conditions
immunoglobulin G4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT07719543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07719543.